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Background: Endothelin-1 may be involved in the development of diabetic microangiopathy. 
We studied the effect of endothelin-1 blockade on myocardial microcirculation during coronary 
stenting.
Patients and methods: Patients with type 2 diabetes and stable coronary artery disease 
undergoing elective percutaneous coronary intervention (PCI) were randomized to bolus dose 
of 500 mg bosentan (n = 4), a dual endothelin receptor blocker, or intracoronary administration 
of 0.03 mmol BQ123 (n = 6), a selective endothelin A-receptor blocker, or placebo (n = 5), 
respectively. Coronary flow reserve (CFR) was measured immediately post-PCI. CFR was also 
measured in five nondiabetic controls post-coronary stenting.
Results: Patients in the placebo group had (P  0.05) lower values of CFR (2.3 ± 1.2) as 
compared to those who received endothelin blockade (n = 10; 3.1 ± 0.7) and nondiabetic controls 
(4.9 ± 2.3). Patients who received BQ123 showed significantly higher CFR (3.3 ± 0.5; P  0.05) 
as compared to those on placebo. Nondiabetic patients had significantly higher CFR as compared 
to patients with diabetes (4.9 ± 2.3 and 2.8 ± 1.0, respectively; P  0.05).
Conclusion: Coronary microvascular dysfunction is present during coronary stenting in patients 
with type 2 diabetes and may be reversed by selective endothelin A-receptor blockade. Targeting 
endothelin system may be of importance in protecting the myocardium against ischemic events 
during elective PCI in type 2 diabetic patients.
Keywords: coronary flow reserve, diabetes, endothelin-1, coronary artery disease, coronary 
angioplasty
Background
Endothelial dysfunction, characterized by an imbalance between endothelium-derived 
vasodilator and vasoconstrictor substances, plays an important role in the pathogenesis 
of vascular complications in diabetes, including microangiopathy.1,2 One important 
feature of endothelial dysfunction is an increased production and biological activity of 
the potent vasoconstrictor and proinflammatory peptide endothelin-1 (ET-1), which has 
been suggested to be involved in the development of cardiovascular disease, including 
diabetic microangiopathy.3 Activation of endothelin A-receptor (ETA) contributes to 
coronary constrictor tone and peripheral and coronary endothelial dysfunction.4,5
Elevated levels of ET-1 are found in patients with type 2 diabetes.6,7 Selective ETA 
receptor blockade by BQ123 markedly increases the nutritive skin microcirculation 
in patients with type 2 diabetes and microangiopathy.8 These results suggest that 
ET-1, through activation of the ETA receptor, is of importance for the regulation of the 
peripheral microcirculation in diabetic patients with microangiopathy.Vascular Health and Risk Management 2009:5 894
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An impaired coronary flow reserve (CFR) has been 
demonstrated in patients with metabolic syndrome and 
type 2 diabetes without clinical evidence of coronary artery 
disease.9,10 Percutaneous coronary intervention (PCI) with 
balloon angioplasty and coronary stenting causes arterial 
injury, resulting in platelet activation, vasoconstrictor release 
and abnormalities in endothelial-dependent vasodilatation, 
which in some patients might lead to adverse effects on the 
microvascular function.11–13 The aim of the present study 
was to evaluate CFR and to determine the effect of dual and 
selective ETA blockade, respectively, on CFR in patients with 
type 2 diabetes undergoing elective coronary stenting.
Material and methods
Patient population
Twenty patients, 15 with type 2 diabetes and five nondiabetic 
patients undergoing nonacute PCI were eligible for the study. 
The patients were admitted for elective PCI because of 
stable one vessel coronary artery disease. Exclusion criteria 
included previous myocardial infarction in the territory of the 
study artery, congestive heart failure and previous coronary 
artery bypass grafting. Informed consent was obtained from 
all patients. The study was approved by the local human ethics 
committee of the Karolinska Institute.
Methods
All patients were treated with aspirin, statins and betablockers. 
Patients with diabetes and three controls were treated with 
angiotensin-converting enzyme inhibitor. All patients 
received a loading dose of 600 mg clopidogrel 12 hours prior 
to PCI, followed by 75 mg on the procedure day. Patients were 
asked to refrain from coffee for at least 12 hours before PCI. 
Patients with diabetes were randomized to receive either dual 
ET-1 receptor blocker bosentan (Group A; n = 4) (Tracleer®, 
Actelion Pharmaceuticals, Allschwil, Switzerland) or the 
selective ETA blocker BQ123 (Group B; n = 6) (Clinalfa, 
Läufelfingen, Switzerland) or placebo tablets (Group C; 
n = 5). Patients in Group A received a bolus dose of 500 mg 
bosentan three hours prior to PCI. In Group B, a total dose 
of 0.03 mmol (9 mL) BQ123 was injected intracoronary 
during the PCI procedure; 0.01 mmol before inflation of the 
predilation balloon, 0.01 mmol after balloon deflation, and 
0.01 mmol after stenting. Group C received placebo tablets 
three hours prior to PCI. The doses of BQ123 and bosentan, 
respectively, were based on previous studies on peripheral 
vascular function.14,15 CFR and fractional flow reserve 
(FFR) were measured post-PCI in all patients including five 
nondiabetic controls.
Pci with coronary stenting
All patients underwent one vessel PCI with coronary stenting 
with either drug-eluting stents or bare metal stents via 
6-French guiding catheters. All patients received the low-
molecular-weight heparin enoxaparin (0.5 mg per kg body 
weight) immediately after insertion of the arterial sheet. 
Intraarterial blood pressure and electrocardiogram were con-
tinuously monitored during PCI. Intracoronary injections of 
nitrate were given to all patients before stenting and before 
measurement of CFR and FFR. None of the patients were 
treated with glycoprotein receptor blocker or bivalirudin.
cFR and FFR measurements
At the end of the PCI procedure, a 0.014-inch fiberoptic 
pressure–temperature sensor-tipped guide wire (Pressure 
Wire Sensor 5; Radi Medical Systems, Uppsala, Sweden) 
was initially held in the proximal part of the target vessel 
for equalizing of the pressure between coronary artery and 
intraaortic pressure, and then advanced through the guiding 
catheter and positioned distal to the PCI-treated segment for 
simultaneous measurements of CFR and FFR, respectively. 
Besides a pressure sensor, this wire has a microsensor at 
3 cm from the floppy tip, which enables simultaneous 
recording of high fidelity temperature with an accuracy of 
0.02 °C. The shaft of the wire, acting as an additional electric 
resistance, can be used as a second thermistor which records 
the input signal at the coronary ostium of any fluid injection 
with a temperature different from blood. Intravenous 
adenosine was used as hyperemic agent. The mean transit 
time at rest and during hyperemia were recorded after rapid 
injection of 3 mL of room temperature saline through the 
guiding catheter as previously described.16 The hyperemic 
and resting mean transit times were measured three times 
and averaged. Thermodilution-derived CFR was calculated 
as the resting mean transit time divided by the hyperemic 
mean transit time.17
Blood analysis
Venous blood samples were obtained 12–16 hours 
after PCI for analysis of cardiac enzymes (CK-MB and 
troponin I). Blood lipids including low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL), and glycosylated 
hemoglobin (HbA1c) were assessed at least four weeks prior 
to PCI according to local laboratory routines.
statistical analysis
Data are shown as means ± standard error (SE). The 
nonparametric Mann–Whitney test was used to analyze the Vascular Health and Risk Management 2009:5 895
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differences between the groups regarding CFR. A two-tailed 
probability value of P  0.05 was considered significant.
Results
The basal characteristics of the patients are presented in 
Table 1. There were no significant differences in age, diabetes 
duration, HbA1c, pre-PCI blood pressure or blood lipids 
between the groups. The PCI procedure was successful in 
all patients. Drug-eluted stents were used in 10 patients 
with diabetes and in two nondiabetic controls. Bare metal 
stents (BMS) were used in remaining patients. There were 
no angiographic signs of PCI-related complications in the 
coronary vessels such as dissection or formation of throm-
bosis with or without peripheral embolization.
Post-PCI CFR was significantly higher in nondiabetic 
controls as compared to patients with diabetes, while diabetic 
patients who received placebo (group C) showed significantly 
lower CFR compared to those who received endothelin 
blocker (Groups A and B) (Figure 1; Table 2). However, 
there was a tendency to lower CFR in diabetic patients who 
received endothelin blocker compared to nondiabetic controls. 
Patients who received bosentan showed lower CFR values 
than those who received BQ123 (Table 2).
Post-PCI FFR were within normal range in all patients 
indicating successful treatment of the epicardial stenosis, 
and there were no significant differences in FFR between 
the groups (Table 2). CK-MB and troponin-I levels were 
normal in all patients prior to PCI and there were no 
significant increases post-PCI in any patients. A resting 
electrocardiogram was obtained in all patients 12–16 hours 
post-PCI and did not show any new changes indicative of 
myocardial ischemia or myocardial infarction following the 
PCI procedure. Intraarterial systolic blood pressure values 
were lower post-PCI compared to pre-PCI in most of the 
patients. Patients in the bosentan group and nondiabetic 
controls had higher blood pressure pre- and post-PCI 
compared to the two other groups (Table 2).
Discussion
Diabetic microangiopathy is characterized by reduced 
microvascular reactivity and impaired nutritive capillary 
circulation.18 ET-1 through increased endothelial dysfunction 
Table 1 Baseline characteristics of 20 patients, 15 with diabetes and five nondiabetic controls, undergoing coronary stenting. Patients 
with diabetes were randomized to endothelin blocker or placebo
Groups Nondiabetic
A (n = 4) B (n = 6) C (n = 5) Controls (n = 5)
Age (y) 69 ± 9 62 ± 4 64 ± 8 62 ± 6
Male/Female (n) 3/1 5/1 3/2 4/1
Diabetes duration (y) 9 ± 5 6 ± 2 6 ± 3 –
smokers (n) 1 0 0 1
HbA1c (%) 6.5 ± 0.6 6.5 ± 0.2 6.6 ± 0.3 –
crcl (mL/min) 89 ± 8 91 ± 7 89 ± 6 92 ± 5
Blood pressure (mmHg)
  systolic 131 ± 6 120 ± 7 123 ± 15 131 ± 16
  Diastolic 76 ± 7 71 ± 9 71 ± 11 75 ± 14
cholesterol (mmol/L)
  Total 4.0 ± 0.3 4.0 ± 0.5 3.8 ± 0.4 3.9 ± 0.4
  LDL 2.5 ± 0.3 2.5 ± 0.4 2.4 ± 0.3 2.4 ± 0.3
  HDL 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.2 ± 0.1
Target vessel (n)
  LAD 2 3 2 3
  LcX 2 1 2 1
  RcA – 2 1 1
Notes:   Values are means ± SE.   There were no significant differences between the groups regarding age, diabetes duration, systolic and diastolic blood pressure or blood lipids. 
group A: patients with diabetes who received bosentan (n = 4). group B: patients with diabetes who received BQ123 (n = 6). group c: Patients with diabetes who received 
placebo (n = 5).
Abbreviations: HbA1c, glycosylated hemoglobin; crcl, creatinine clearance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; LAD, left anterior descending artery; 
LCX, left circumflex artery; RCA, right coronary artery; SE, standard error.Vascular Health and Risk Management 2009:5 896
Östlund Papadogeorgos et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
has been suggested to contribute to impaired microvascular 
reactivity in patients with diabetes.8 There is increasing 
evidence  of  the  presence  of  disturbed  myocardial 
microvascular function in patients with diabetes and 
metabolic syndrome.9,10 Disturbed microvascular function 
in the myocardium of patients with diabetes may play an 
important role in the pathogenesis of systolic and diastolic 
myocardial dysfunction in absence of epicardial coronary 
artery disease. As in peripheral microcirculation, an impaired 
coronary microvascular function is seen during ischemic 
and/or mechanical stress, eg, PCI, which is suggested to 
partly explain poor long-term outcome in diabetic patients 
undergoing coronary revascularization.19
The present study was undertaken to explore the 
hypothesis that in patients with type 2 diabetes, myocardial 
microvascular function is impaired during percutaneous 
coronary intervention, and that it can be restored by 
endothelin-receptor blockade. The results show that 
coronary microvascular dysfunction is present after PCI with 
coronary stenting in patients with type 2 diabetes, and that 

















Figure 1 Coronary flow reserve (CFR) post-coronary stenting in 20 patients; 15 with diabetes and five nondiabetic controls. Patients with diabetes were randomized to 
bosentan (group A; n = 4), BQ123 (group B; n = 6) or placebo (group c; n = 5).
Table 2 Post-PCI values of CFR, FFR, and intraarterial blood pressure in 15 patients with diabetes and five nondiabetic controls 
undergoing coronary stenting. Patients with diabetes were randomized to endothelin blocker or placebo
Groups Nondiabetic 
Controls (n = 5) A (n = 4) B (n = 6) C (n = 5)
cFR 2.8 ± 1.0 3.3 ± 0.5a 2.3 ± 1.2 4.9 ± 2.3b
FFR 0.97 ± 0.02 0.96 ± 0.01 0.97 ± 0.02 0.96 ± 0.01
Blood pressure (mmHg)
systolic 130 ± 5 120 ± 4 122 ± 14 127 ± 9
Diastolic 76 ± 6 69 ± 8 70 ± 11 70 ± 9
Notes:   Values are means ± se. aP  0.05 as compared to patients on placebo (group c). bP  0.05 as compared to patients with diabetes (n = 15).
Abbreviations: CFR, coronary flow reserve; FFR, fractional flow reserve; PCI, percutaneous coronary intervention; SE, standard error.Vascular Health and Risk Management 2009:5 897
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In type 2 diabetes, there is a complex interaction 
between impaired insulin sensitivity, vascular endothelial 
dysfunction, and hypertension, which seems to play an 
important role in the development of functional disturbances 
in the microcirculation. Impaired insulin sensitivity is 
associated with a modification of arterial resistance, 
increased microvascular resistance and macro- and 
microvascular endothelial dysfunction.20–23 ET-1 is one of 
the most potent vasoconstrictors described and has been 
suggested to contribute to vascular endothelial dysfunction 
in diabetes. Elevated levels of ET-1 are found in patients with 
type 2 diabetes,6,7,24 and ET-1-induced reduction in insulin 
sensitivity may take part in the development of the metabolic 
syndrome.25 In diabetes mellitus, a primary disturbance in 
ET-1 production from vascular endothelium exists as an 
early phenomenon rather than a result of advanced stage of 
the disease.26,27
Furthermore, ET-1 may contribute to the development of 
endothelial dysfunction, and consequently insulin resistance, 
by increasing the production of reactive oxygen species, 
mainly superoxide anion, in the vasculature.28–30 Two receptor 
subtypes, endothelin A- and B-receptors (ETA and ETB), 
mediate the effects of ET-1. Vascular smooth muscle cells 
express both ETA and ETB, while endothelial cells express 
primarily ETB.31 On smooth muscle cells, ETA mediates 
vasoconstriction and mitogenesis, while ETB receptor 
has a dual function and has been shown to cause both 
vasoconstriction and vasodilation.32,33 ETA receptor activation 
contributes to coronary constrictor tone and peripheral and 
coronary endothelial dysfunction.4,5
In patients with acute myocardial infarction, microvascular 
function in the myocardium measured by CFR is impaired 
due to several complex factors such as distal embolization, 
activation of vasoactive peptides, eg, ET-1, and reperfusion 
injury through several plausible pathways, eg, protein 
kinase C activation. Assessment of post-reperfusion CFR in 
patients with acute myocardial infarction seems to predict 
left ventricle function recovery and future short-term cardiac 
events.34–37 Patient with diabetes have poor long term outcome 
after coronary artery stenting partly because of being more 
prone to distal embolization and exaggerated myocardial 
microvascular dysfunction during PCI.20,38 In the study by Kini 
and colleagues, patients with diabetes showed significantly 
lower CFR after PCI as compared to nondiabetic patients 
despite treatment with the glycoprotein receptor inhibitor 
abciximab suggesting more pronounced microvascular 
dysfunction in patients with diabetes.19,20 In the present study, 
impaired CFR post-PCI was partly reversed by intracoronary 
injection of selective ETA blocker BQ123 in patients with 
diabetes. However, CFR remained lower in patients with 
diabetes as compared to nondiabetic patients despite dual 
and selective endothelin receptor blockade, respectively. 
These results indicate that beside ET-1, other neurohumoral 
and/or inflammatory mechanisms may be involved in the 
pathogenesis of microvascular dysfunction during coronary 
stenting in diabetic patients.
CFR was somehow lower in bosentan group as compared 
to BQ123 group, and only slightly higher compared to patients 
in placebo group. The difference in efficacy between dual and 
selective endothelin receptor blockade with regard to reversal 
of myocardial microvascular dysfunction may be due to the 
different action of ETA and ETB receptors in various vascular 
beds.5,39 In the study by Halcox and colleagues, bosentan, in 
opposite to BQ123, did not produce microvascular coronary 
vasodilation despite epicardial vasodilation. A significant 
effect of 500 mg bosentan on peripheral vascular endothelial 
function has been demonstrated in previous studies,15 
however, a low local myocardial concentration of the drug 
may also partly explain why bosentan did not produce the 
same response as intracoronary injected BQ123.
Coronary flow reserve is impaired in arterial hyper-
tension40,41 and independently associated with myocardial 
diastolic function, seen early in diabetic patients.42 Blood 
pressure prior to PCI was well controlled in all patients prior 
to PCI, however, intraarterial measured systolic and diastolic 
blood pressures at baseline was higher in nondiabetic controls 
and patients in BQ123 group, and remained higher in these 
two groups at the end of PCI procedure. Despite higher 
blood pressure, CFR was higher in patients receiving BQ123, 
indicating a positive effect of selective ETA blockade on myo-
cardial microcirculation.
There are limitations with the present study. Small 
numbers of patients are included in each group in this 
pilot-study. However, a significant effect on CFR seems to 
have been produced by intracoronary BQ123 in such a limited 
study population indicating that ET-1 through ETA activation 
is important in regulation of myocardial microcirculation in 
diabetic patients. Another limitation is that serum ET-1 levels 
were not analyzed. However, serum levels of ET-1 are not a 
reliable measure of its biological activity in the vasculature, 
or expression of ET-1 receptors. Finally, there is no matched 
placebo group against BQ123 group, but the probability that 
intermittent intracoronary injection with physiological saline 
of a total volume of 9 mL would influence CFR is low.
In conclusion, the results of the present study show 
that selective ETA receptor blockade attenuates coronary Vascular Health and Risk Management 2009:5 898
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microvascular dysfunction after coronary stenting in patients 
with type 2 diabetes. The results need to be confirmed in a 
larger double-blind placebo-controlled study.
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